Trial Information

Summary: Allogeneic Stem Cell Transplantation with a Novel Conditioning Therapy Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies

You have/your child has been asked to participate in this research study because you have/your child has one of the following diseases:

A.      Acute Myelogenous Leukemia (AML)

B.      Myelodysplastic syndromes with intermediate or high-risk disease

C.      Granulocytic sarcoma (chloroma) with or without bone marrow involvement

D.      Mixed lineage leukemia if the induction therapy was directed predominantly against AML

The purpose of this research study is to evaluate the safety and usefulness of Helical Tomotherapy (HT) plus the chemotherapy drugs fludarabine and melphalan as a preparative treatment for bone marrow transplantation from related or matched unrelated donors in the treatment of AML and AML subtypes.  The treatment will last one or two months.  After treatment is over, your/your child’s medical condition will be followed indefinitely. 

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:31:13 PM